Show simple item record

dc.contributor.authorHaldorsen, Karsteinen_US
dc.contributor.authorBjelland, Ingvaren_US
dc.contributor.authorBolstad, Anne Isineen_US
dc.contributor.authorJonsson, Rolanden_US
dc.contributor.authorBrun, Johan Gorgasen_US
dc.date.accessioned2012-01-18T11:50:44Z
dc.date.available2012-01-18T11:50:44Z
dc.date.issued2011-10-13eng
dc.PublishedArthritis Research and Therapy 2011, 13:R167en
dc.identifier.issn1478-6354
dc.identifier.urihttps://hdl.handle.net/1956/5455
dc.description.abstractIntroduction: Fatigue is prevalent in primary Sjögren’s syndrome (pSS), and contributes to the considerably reduced health related quality of life in this disease. The symptom is included in proposed disease activity and outcome measures for pSS. Several studies indicate that there is an inflammatory component of fatigue in pSS and other chronic inflammatory rheumatic diseases. The purpose of this study was to investigate fatigue change in pSS in a longitudinal study, and explore whether any clinical or laboratory variables at baseline, including serum cytokines, were associated with a change in fatigue scores over time. Methods: A clinical and laboratory investigation of 141 patients fulfilling the American-European consensus criteria of pSS was undertaken in the period May 2004 to April 2005. Median time since diagnosis was 5.5 years. Examinations included the fatigue questionnaires: fatigue severity scale (FSS), fatigue visual analogue scale (VAS), functional assessment of chronic illness therapy - fatigue (FACIT-F) and medical outcome study short form-36 (SF- 36) vitality, which were repeated in a follow-up investigation in January and February 2010. Results: A total of 122 patients (87%) responded at both time-points. Thirty-five percent of patients experienced a clinically significant FSS increase. On the group level, fatigue measures did not change except that there was a slight deterioration in SF-36 vitality score. High serum anti-Sjögren’s syndrome A antigen (anti-SSA) showed weak associations with high baseline fatigue, and patients with increasing fatigue had lower baseline unstimulated whole salivary volume. Weak associations between increasing fatigue and serum immunoglobulin G (IgG), and the pro-inflammatory cytokine interleukin-17 (IL-17), were observed. Baseline sicca symptoms correlated with higher fatigue both at baseline and with increasing fatigue over time. Linear regression analysis did not identify any predictive ability of clinical or laboratory measures on fatigue change over time. Conclusions: Fatigue remained mainly unchanged over time. Using multivariate models did not reveal any clinical or laboratory predictors of fatigue change over time.en_US
dc.language.isoengeng
dc.publisherBioMed Centraleng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/2.0/eng
dc.titleA five-year prospective study of fatigue in primary Sjögren’s syndromeen_US
dc.typePeer reviewed
dc.typeJournal article
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2011 Haldorsen et al.; licensee BioMed Central Ltd.
dc.identifier.doihttps://doi.org/10.1186/ar3487
dc.identifier.cristin874681
dc.subject.nsiVDP::Medical disciplines: 700::Clinical dentistry disciplines: 830eng


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY